Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

dti announces nominees for 2008 Science and Technology Awards
2008-10-03

 

At the announcement of the nominees for the 2008 dti Technology Awards were, from the left: Prof. Schalk Louw, Department of Zoology and Entomology, Mr Sipho Zikode, Deputy Director General at the Department of Trade and Industry (dti), Dr Romilla Maharaj, Executive Director: Human and Institutional Capacity Development at the National Research Foundation (NRF), and Mr Ephraim Baloyi, Director: Innovation and Technology at the dti.

Mr Michael Chung, master’s student in Plant Pathology, explaining some of the research conducted in the Centre for Plant Health Management (Cephma).

Prof. Schalk Louw, Department of Zoology and Entomology, and Mr Ephraim Baloyi, Director: Innovation and Technology at the dti in the Cephma laboratory.

   
dti announces nominees for 2008 Science and Technology Awards

The Department of Trade and Industry’s (dti) Deputy Director-General, Mr Sipho Zikode, yesterday announced the nominees for the 2008 dti Technology Awards which will take place on 30 and 31 October in Bloemfontein.

The purpose of these annual awards is to recognise those researchers, private institutions and students who performed well in terms of innovation and technology development, says Mr Ephraim Baloyi, Director: Innovation and Technology at the dti.

The awards are a combination of the Annual Awards of the different dti programmes supporting technology in industry. They are the Technology and Human Resources for Industry Programme (THRIP), administered by the National Research Foundation (NRF), the Support Programme for Industrial Innovation (SPII), administered by the Industrial Development Corporation, and seda Technology Programme (stp), administered by the Small Enterprise Development Agency.

The dti delegation also visited the laboratory of Prof. Schalk Louw of the UFS to view the work of this former dti Technology Awards recipient. Prof. Louw is a member of the UFS Centre for Plant Health Management (Cephma) team that won a 2007 Technology Award for groundbreaking research work on kenaf (a South African commercial fibre crop used, amongst others, in the automotive industry). The research of the Cephma team is supported by the NRF’s THRIP programme.

The awards are hosted in a different province each year to increase awareness around the dti’s technology support for researchers, small enterprises, large industries and business incubators.

Media Release
Issued by: Leonie Bolleurs
Tel: 051 401 2707
Cell: 083 645 5853
3 October 2008

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept